Trial Profile
Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Oxyntomodulin (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms MK-0000-222
- Sponsors Merck Sharp & Dohme
- 24 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 05 Jul 2013 Primary endpoint added as reported by ClinicalTrials.gov.
- 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.